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Available online 22 October 2012Nontyphoidal isolates of Salmonella (NTS), particularly Salmonella Typhimurium, are a major
cause of invasive bacteremia in Africa. Despite this, no vaccine against NTS is currently
available for use in humans. If a NTS vaccine is to be developed in a timely manner, there is a
need to develop assays to assess its in vivo efficacy. Assessment of potential efficacy of
candidate vaccines in preclinical models is important for proof-of-concept and reduces
attrition of vaccines in clinical trials. Serum bactericidal assays (SBA) are often used to assess
the functional activity of vaccine-induced antibody responses targeted against Gram-negative
bacteria with results given as the maximum dilution of serum that can effect bacterial killing.
Previously we have found evidence for a protective role for antibody-induced complement-
mediated killing of NTS in African children using an undiluted whole serum SBA. However,
endogenous complement in diluted human sera is limiting and insufficient to effect
bactericidal activity against S. Typhimurium beyond two two-fold dilutions. In the current
study, we examined the requirements for SBA against NTS using baby rabbit serum (BRS) as an
exogenous source of complement. We found that the amount of complement required for
antibody-mediated bactericidal activity is much higher for the invasive African S. Typhimurium
isolate D23580, compared with the laboratory S. Typhimurium LT2 and Salmonella Paratyphi A
CVD1901. While 20% BRS was sufficient to kill LT2 and CVD1901, 75% BRS was needed to kill
D23580. Our findings demonstrate that one concentration of exogenous complement is not
suitable for SBA against all Salmonella isolates. To develop SBA to assess the in vivo efficacy of
Salmonella vaccines, it is necessary to optimize the assay for the Salmonella isolates against which
the vaccine is targeted.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license. Keywords:
Serum bactericidal assay
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Complement1. Introduction
Salmonella enterica causes a spectrum of diseases, includ-
ing typhoid and paratyphoid fever, and gastroenteritis
(Everest et al., 2001; Hohmann, 2001; Boyle et al., 2007),A, serum bactericidal
equence typing; CFU,
accharide.
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Y-NC-ND license. and is a major threat to public health. S. enterica serovar Typhi
is the causative agent of typhoid fever. Paratyphoid fever, a
clinically-similar disease with less prevalence, is caused
by S. enterica serovar Paratyphi A, B and C. In developed
countries, nontyphoidal isolates of Salmonella (NTS) usually
cause gastroenteritis. In Africa, NTS, especially S. enterica serovar
Typhimurium, are a common cause of invasive disease, in
particular bacteremia. NTS bacteremia in sub-Saharan Africa
primarily occurs in children under 2 years of age and HIV-
infected individuals (Graham et al., 2000; Graham, 2002, 2010;
Brent et al., 2006; Bronzan et al., 2007). The estimatedminimum
incidence of NTS bacteremia is 175 per 100,000 in Kenyan
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lack of specific clinical presentation of NTS bacteremia makes
diagnosis difficult. In addition, increased drug resistance and the
emergence of new multi-drug resistant isolates (Hohmann,
2001; Mirza et al., 1996) have added to the burden of this often
fatal disease. These findings emphasize the need for an effective
vaccine against NTS. Currently, none is available for use in
humans.
The role of antibody in protection against Salmonella has
been well established. Adoptive transfer of antibodies confers
protection against virulent Salmonella challenge (Mastroeni
et al., 1993; McSorley and Jenkins, 2000). The importance of
antibodies has also been emphasized by studies on Vi
polysaccharide, which elicit T cell-independent antibody
production and confer protection (Acharya et al., 1987). A
key assessment of most vaccines is their ability to induce
specific antibody production. However, high antibody levels
alone are insufficient, since vaccine-induced antibodies need
to be protective. A common in vitro assay aimed at providing
functional information about potential in vivo protection is
the serum bactericidal assay (SBA). This assesses the
complement-dependent bactericidal activity of antibodies in
sera against particular bacterial isolates. SBA have been used
to gauge natural immunoprotection against Salmonella in
Africans (MacLennan et al., 2008; Pulickal et al., 2009), and
are reported to be the best immunological surrogate of
protection against meningococcal disease (Frasch et al.,
2009). Using an undiluted whole human serum SBA, our
previous data demonstrate the necessity of both antibody
and complement for in vitro killing of Salmonella and provide
evidence that bactericidal antibody protects against invasive
NTS disease in Africans (MacLennan et al., 2008).
There are a number of variables associated with the
design and optimization of SBA. Optimum conditions re-
quired for Salmonella SBA have not been reported. In the
present study, we evaluated the complement requirements
of SBA for three isolates of Salmonella: invasive African
Salmonella Typhimurium D23580, laboratory S. Typhimurium
LT2, and laboratory Salmonella Paratyphi A CVD1901, using
both endogenous and exogenous complement.
2. Materials and methods
2.1. Study sera
Blood from healthy volunteers (1 European and 1 Asian)
was allowed to clot and serum was separated within 2–3 h.
Aliquots of sera (donor 1 and 2) were then stored at−80 °C
to preserve complement function. Pooled Malawian serum
was separated from blood samples taken from healthy adults
in Blantyre, Malawi, and pooled prior to storage at −80 °C.
All individuals had no known clinical history of Salmonella
infection. Ethical approval was granted by the College of
Medical Research and Ethics Committee, College of Medicine,
University of Malawi.
2.2. Bacterial isolates
Three Salmonella isolates were used: S. Typhimurium
D23580, S. Typhimurium LT2 and S. Paratyphi A CVD1901.
S. Typhimurium D23580 is an invasive African isolate withMLST sequence type ST313 from a bacteremic child in Blantyre,
Malawi (MacLennan et al., 2008; Kingsley et al., 2009). It is
representative of most NTS isolates from bacteremic individuals
in Malawi since 2002 and is sensitive to killing by healthy
human adult serum (Kingsley et al., 2009; MacLennan et al.,
2008). S. Typhimurium LT2 is a commonly-used laboratory
isolate of S. Typhimurium (Hoiseth and Stocker, 1981). S.
Paratyphi A CVD 1901 is a laboratory guaA− mutant from the
Center for Vaccine Development, University of Maryland School
forMedicine (Gat et al., 2011). Its attenuation permits the use of
CVD 1901 in BSL2 containment laboratories. This isolate is
unable to synthesize guanine. All bacterial isolates were grown
aerated in 10 ml LB in loose-capped 50 ml Falcon tubes at 37 °C
with shaking at 180 rpm.
2.3. Salmonella serum bactericidal assay
For serum bactericidal assays involving endogenous com-
plement, 5 μl viable Salmonellae at 2 h log-growth phase and
an OD of approximately 0.2 (with shaking at 180 rpm) was
added to 45 μl undiluted or PBS-diluted serum (final Salmo-
nella concentration 1×106 CFU/ml) and incubated at 37 °C
with the number of viable Salmonellae determined by serial
dilution on Luria Bertani (LB) agar after 0, 45, 90, and 180 min.
For serum bactericidal assays with exogenous complement,
5 μl viable bacteria in log-growth phase was added to 45 μl of
a mix of PBS-diluted heat-inactivated serum and baby rabbit
serum (BRS). Test serumwas heat-inactivated by incubating at
56 °C for 30 min. BRS were from AbD Serotec (Kidlington, UK)
and Pel-Freez/Invitrogen (Milan, Italy).
2.4. Anti-Salmonella antibody assay
5 μl Salmonellae at 3 h log-growth phase was mixed
with 45 μl 10% serum (final Salmonella concentration
2×108 CFU/ml) as previously described (MacLennan et
al., 2008). Antibody bound to bacteria was detected with
FITC-conjugated polyclonal goat anti-mouse IgG, IgA and
IgM antibody (Sigma-Aldrich, Milan, Italy) prior to FACS
analysis on a FACSCanto instrument (BD Biosciences, Milan,
Italy).
2.5. LPS extraction
Overnight bacterial cultures were washed with 0.9% (w/v)
NaCl and boiled in a solution of 60 mM Tris–HCl, 2% (v/v) SDS
and 1 mM EDTA pH 6.8. RNase/DNase solution (Sigma-Aldrich)
was then added at a final concentration of 100 μg/ml and
incubated at 37 °C. Following this, proteinase K (Sigma-Aldrich)
was added at a final concentration of 50 μg/ml. The LPSmixture
was incubated overnight at 50 °C and then stored at 4 °C until
use.
2.6. LPS gel electrophoresis and silver staining
Tris–acetate sample buffer (Invitrogen) was added to the
extracted LPS. The mixture was then boiled and separated on
a 16% Tricine gel (Invitrogen). After electrophoresis, the gel
was fixed in 40% ethanol, 5% acetic acid for an hour before a
5 min incubation with an addition of 0.7% periodic acid. After
three washes with distilled water, the gel was stained with
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developed with 0.5% (v/v) citric acid and 0.05% (v/v)
formaldehyde until the appropriate staining intensity was
achieved. The reaction was terminated with 5% methanol
(Tsai and Frasch, 1982).
3. Results
3.1. Diluted human serum has limited bactericidal activity
against S. Typhimurium
All three Salmonella isolates used in the study, S.
Typhimurium D23580, S. Typhimurium LT2 and S. Paratyphi
A CVD1901, were morphologically smooth with long-chain
lipopolysaccharide, as indicated by the characteristic ladder
appearance of O-antigen repeating units of lipopolysaccharide
visualized by SDS-PAGE with silver-staining (Fig. 1). This
indicates that any susceptibility to serum killing is not due to
the absence of the lipopolysaccharide O-antigen chain. WeFig. 1. LPS profiles of Salmonella isolates used in serum bactericidal assays
(SBA). LPSwas extracted fromovernight cultures of S. TyphimuriumD23580, S.
Typhimurium LT2 and S. Paratyphi A CVD1901 and separated on a Tricine
SDS-PAGE gel which was silver stained.confirmed by flow cytometry that all sera used contained IgG,
IgA and IgM against the three bacterial isolates. BRS did not
contain any IgG, IgA and IgM against the isolates (Fig. 2).
We examined the bactericidal activity of diluted fresh
human serum in SBA against the three Salmonella isolates.
When used undiluted, all three human sera killed the isolates
(where killing is defined as any reduction in viable bacterial
count compared with the initial Salmonella concentration).
More specifically, all three human sera killed S. Typhimurium
D23580 by 2–3 log10 and S. Typhimurium LT2 by 3 log10 at
180 min, while S. Paratyphi A CVD1901 was killed by 3 log10
within 45 min (Fig. 3). Heat-inactivation (to remove comple-
ment activity) abolished serum bactericidal activity, consis-
tent with bacterial killing being complement-dependent as
previously shown for D23580 (MacLennan et al., 2008).
S. Paratyphi A CVD1901 was highly sensitive to serum killing
with all dilutions of human sera tested killing the bacteria.
1/2, 1/4, 1/8 dilutions effected a 3 log10 kill and 1/16 dilution
a 1 log10 kill by 180 min. The bactericidal activities of the
human sera against S. Typhimurium isolates were more
affected by serum dilutions, particularly D23580 — the
highest dilution of the human sera that could still kill LT2
was 1/8 for donor 1 and donor 2 sera, and 1/4 for the pooled
Malawian serum, while 1/4, but not 1/8 dilution of all sera
killed D23580. These findings indicate the limitation ofFig. 2. Levels of anti-Salmonella antibody in human sera used in SBA.
Antibody deposition on S. Typhimurium (STm) D23580, S. Typhimurium (STm)
LT2 or S. Paratyphi A (SPt) CVD1901 in log-growth phase was measured by flow
cytometry. Each point represents each of the 3 human sera or BRS.
Fig. 3. Bactericidal activity against Salmonella isolates of human serum as source of antibody and complement. SBA was performed with 1×106 Salmonella/ml and
the number of viable bacteria was determined following 45, 90, and 180 min of serum exposure. S. Typhimurium D23580, S. Typhimurium LT2 and S. Paratyphi A
CVD 1901 were used as target isolates and three human sera (sera from donor 1, donor 2 and Malawian adults) were used as antibody source. The human sera
were either non-diluted (Nd) or diluted (1/2, 1/4, 1/8, 1/16) in PBS. Heat-inactivation (HI) of human sera was performed by incubating the sera at 56 °C for
30 min.
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against S. Typhimurium. Since both antibody and complement
are co-diluted, the individual contributions of anti-Salmonella
antibody and complement to killing of Salmonella cannot be
determined. Hence, it is necessary to provide an exogenous
source of complement in S. Typhimurium serum bactericidal
assay when serial dilutions of human serum are used as the
source of antibody.
3.2. Fresh BRS is unable to kill S. Typhimurium in the absence of
antibody
BRS is commonly used as an exogenous source of
complement in serum bactericidal assays and was used as
the exogenous source of complement in this study. We first
measured the ability of BRS alone to kill Salmonella by
determining the viable bacterial numbers following exposure
to different percentages (20%, 50%, 75%, 100%) of BRS over a
3 h time course.
All percentages of BRS tested (both AbD Serotec and
Pel-Freez BRSs) did not kill S. Typhimurium D23580 and LT2(Fig. 4). The viable bacterial count of S. Typhimurium D23580
increased by approximately 1 log10 in all percentages of BRS
tested, while S. Typhimurium LT2 was bacteriostatic. With S.
Paratyphi A CVD1901, higher percentages of both AbD Serotec
and Pel-Freez BRS (100% and 75%) could kill the bacteria by 1–2
log10 over 180 min (Fig. 4). This antibody-independent killing
was removed when BRS was heat-inactivated.
3.3. In the presence of antibody, a high percentage of BRS is
required to kill invasive African S. Typhimurium D23580
The difference in susceptibility of the three Salmonella
isolates to killing by neat and diluted human serum suggested
that there will be differences in the amount of BRS required for
bactericidal activity in the presence of antibody. Using AbD
Serotec BRS as the exogenous complement source and heat-
inactivated diluted pooled Malawian serum for antibody, we
investigated the amount of BRS required to kill the three
bacterial isolates. With S. Typhimurium D23580 as the target
isolate and 1/40 or 1/400 diluted human sera as antibody source,
bacterial growth occurred with 20% BRS, and bacteriostasis with
Fig. 4. Bactericidal activity of BRS in the absence of an antibody source. SBA was performed with 1×106 Salmonella/ml and the number of viable bacteria was
determined at t=45, t=90, and t=180 min. S. Typhimurium D23580, S. Typhimurium LT2 and S. Paratyphi A CVD1901 were used as target isolates and killing
by different percentages of BRS (AbD Serotec), in the absence of an antibody source, was examined.
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three percentages of BRS killed S. Typhimurium LT2 at 1/40, 1/
400 and 1/4000 diluted human serum, although with limited
killing at 1/4000. With S. Paratyphi A CVD1901 as the target
isolate, all percentages of BRS were bactericidal at all serum
dilutions tested (1/4 to 1/40,000) with a 3 log10 kill at lower
serum dilutions (1/40 and 1/400) at 180 min and more limited
killing at higher serum dilutions. Heat-inactivation of the
BRS removed bactericidal activity. For all three isolates, 1/4
diluted human serum gave reduced or no bactericidal
activity which appears to be a prozone effect (Lieberman et
al., 1988; Zollinger andMandrell, 1983). Similar results were
obtained when the assay was repeated with BRS from
Pel-Freez (Fig. A.1). The findings indicate that the amount
of BRS used in serum bactericidal assay is critical and that the
amount of BRS needed for killing is dependent on the target
bacterial isolate.
To verify that the observations made were not specific to
the pooled Malawian serum used, we repeated the assay
using two sera from 2 healthy individuals (1 European and 1
Asian) as the antibody source (donor 1 and 2). The
bactericidal activity of the three sera against the threeSalmonella isolates was similar across the three BRS
percentages tested (Figs. A.2–A.3).
4. Discussion
One method to detect functional antibodies in vaccinated
or non-vaccinated human individuals by SBA is to use fresh
undiluted human sera as both antibody and complement
source. One advantage is that it is the most physiological and
closest to ‘real-life’ scenario of bacteria in the bloodstream
during invasive disease. However, sera from vaccinated
individuals are often limited in quantity and are not
necessarily handled to preserve complement integrity.
Whole serum SBA does not permit the determination of a
bactericidal titer, the minimum dilution of serum that can kill
bacteria. Here, we examined the serum bactericidal activity
of diluted fresh human serum against S. Typhimurium
D23580, S. Typhimurium LT2 and S. Paratyphi A CVD1901.
Our findings indicate that endogenous complement in
diluted human sera can be limiting in a SBA against
Salmonella. A 1/4 dilution of the human sera removed the
bactericidal activity against S. Typhimurium D23580. This is
Fig. 5. BRS requirement of Salmonella SBA using pooled human serum from Malawian adults as antibody source and AbD Serotec BRS as complement source. SBA
were performed with 1×106 Salmonella/ml and the number of viable bacteria was determined at t=45, t=90, and t=180 min. S. Typhimurium D23580,
S. Typhimurium LT2 and S. Paratyphi A CVD1901 were used as target isolates and serum from pooled Malawian adults was used as antibody source. The human
serum (HS) was first heat-inactivated (HI) and then diluted (1/4, 1/40, 1/400, 1/4000, 1/40000). BRS from AbD serotec was used as the exogenous source of
complement (at 20%, 50% or 75%).
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(a 1/10 dilution) was insufficient to effect bactericidal
activity against S. Typhimurium D23580 (MacLennan et al.,
2008). Therefore, an exogenous source of complement is
required when diluted human sera are used. Furthermore, if
testing the efficacy of antibody to Salmonella generated in
mice, SBA require an exogenous source of complement. This
is because there is an absence of bactericidal activity in
mouse sera due to impaired complement function (Siggins et
al., 2011).
As most human sera contain naturally-acquired anti-
Salmonella antibody, it is difficult to obtain human sera
lacking anti-Salmonella antibody to use as an exogenous
source of complement for SBA. Readily available BRS has been
commonly used as the source of complement in SBA. BRS
does not contain anti-Salmonella antibodies, making it an
appropriate source of complement for Salmonella SBA. We
evaluated the optimum BRS requirement for Salmonella SBA.
Using human sera, which included adults fromMalawi where
NTS infections are common, we found that the amount of
complement used in Salmonella SBA is critical and is
dependent on the target bacterial isolate. While 20% BRS
is sufficient to effect bactericidal activity against S. TyphimuriumLT2 and S. Paratyphi A CVD1901, 75% BRS is needed to effect
bactericidal activity against S. TyphimuriumD23580. S. Paratyphi
A CVD1901 is the most sensitive of the isolates tested to serum
killing. It has been published that Rck, an outer membrane
protein encoded on the virulence plasmid of S. Typhimurium,
binds to complement regulatory protein factor H, thus inhibiting
the complement activation via the alternative pathway (Ho et
al., 2010). Both S. Typhimurium D23580 and LT2 have the
virulence plasmid harboring the rck gene (MacLennan et al.,
2008; Rychlik et al., 2006), which might confer the two S.
Typhimurium isolates protection against complement killing via
the alternative pathway in the absence of antibody, while still
remaining susceptible to complement killing via the classical
pathway in the presence of antibody. Unlike S. Typhimurium, S.
Paratyphi A lacks the virulence plasmid and hence lacks the rck
gene (Baumler et al., 1998). The absence of the rck gene in S.
Paratyphi A might result in greater sensitivity to serum
killing and would explain why BRS alone in the absence of
specific S. Paratyphi A antibody could kill the bacteria.
Alternatively, since differences in the structure of the
O-antigen polysaccharides can affect complement deposi-
tion, such differences could account for the variation in
susceptibility to killing (Jimenez-Lucho et al., 1987). These
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bactericidal activity against S. Paratyphi A, which is
insufficient to effect in vitro serum bactericidal activity
against S. Typhimurium (MacLennan et al., 2008).
A potential clinical implication of the finding that a high
complement level is needed to effect bactericidal activity
against the invasive S. Typhimurium D23580 relates to the
association of S. Typhimurium infections with malaria. This
clinical association is well recognized in Africa (Graham et al.,
2000; Bronzan et al., 2007). Hypocomplementemia, a marked
decrease of serum complement components, is often ob-
served in children and adults with acute malaria (Dulaney,
1947; Siddique and Ahmed, 1995). Hypocomplementemia in
African patients with malaria may therefore increase suscep-
tibility to S. Typhimurium, giving rise to co-infection with
malaria and Salmonella.
These findings have clinical implications in the develop-
ment of a vaccine for S. Typhimurium infections in Africa. We
demonstrated that the same parameters for SBA cannot be
applied to all bacterial isolates. SBA using low amounts ofFig. A.1. BRS requirement of Salmonella SBA using pooled human serum from Malaw
were performed as described in Fig. 5.complement would not be sensitive enough to detect bacteri-
cidal activity against the invasive African S. Typhimurium isolate
D23580. This has practical implications for SBA used during
preclinical studies that are aimed at gauging potential in vivo
protection and also for SBA with sera from clinical trials
that are aimed at providing information about protection
in humans. Hence, this work facilitates the implementation
of a flexible SBA that can assess responses to multiple
Salmonella isolates and aid the development of a vaccine to
this deadly pathogen.Acknowledgments
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